跳至主要内容

IND Filing

 Medicilon is the first CRO to offer preclinical animal testing service for the global pharmaceutical companies in China. We provide the IND application for the preclinical services. Medicilon is the CRO that fulfill both the China and US GLP standards. Medicilon could submit the application for both US FDA and CFDA for your new drug. Since 2004, we have successfully helped our clients to submit their new drug application to US FDA and CFDA and met the requirements of the US FDA and CFDA. We have undergone several inspections and passed all of them. Medicilon will provide an efficient, cost-effective and professional service to help our clients to achieve their goals.

Medicilon’s IND Application Service

With an insight into drug regulatory policy environment of China and the United States, Medicilon’s drug registration is able to provide CFDA IND application, USFDA IND / ANDA application services for domestic customers and CFDA IND / ANDA application service for foreign customers.
Medicilon’s drug registration group not only provides entire IND filing to our customers, but also provides the clients who only have IND filing requirements.

Medicilon’s IND Filling Services

  • Preparation and submission of CFDA IND documents for domestic customers
  • Proxy of USFDA IND/ANDA documents submission for domestic customers
  • Proxy of CFDA IND/ANDA documents submission for foreign customers
  • Project management services (only for customers with complete preclinical study)
  • Review, collation and technical evaluation of the IND / ANDA filing documents provided by the customer; and then complete the preparation, review, editing and finalization

Before the submission of the application materials, Medicilon’s IND application department will organize an internal technical communication meeting about a detailed analysis of the declaration project. After the submission of the application materials, there will be a senior reporting person in charge of the continuous communication with the regulatory body, and ensure a real-time follow-up reporting progress until the declaration of the successful completion.
In addition, according to the recent analysis of domestic drug filing data, the Chinese government will setup some innovative policies which have been evident in the drug declaration. Therefore, it is expected that the innovative drugs in China will have a good momentum of development.

Advantages of IND Application Services

  • A professional IND/ANDA research team can provide one-stop research, full project management and reporting services
  • Rich knowledge resources of CFDA/USFDA experts can provide targeted technology, regulations and reporting strategy recommendations

Medicilon’s IND application group is leading by our VP and experienced researchers, who dedicate to provide our customers a satisfactory integrated preclinical services.

Service for Complete Preclinical Study and Independent IND Application Project

(The whole set of preclinical studies include: APIs process and quality research, preparation process and quality research, efficacy, drug and safety evaluation)

  • 3 IND Packages Accepted by USFDA
  • 3 IND Packages Accepted by TGA
  • 15 IND Packages Approved by CFDA
  • 10 IND Packages Already Submitted to CFDA

Service for Complete Preclinical Study and Public IND Application Project

(The whole set of preclinical studies include: APIs process and quality research, preparation process and quality research, efficacy, drug and safety evaluation)

  • FZ016, chemical medicine category 1, planned CFDA and USFDA IND declaration, already got clinical approval of CFDA in August 2016, and will be declared USFDA.
  • X842, chemical medicine category 1, planned CFDA and EMEA and USFDA IND declaration, already submitted EMEA CTA documents in November 2016 and CFDA IND documents in January 2017, and will be declared USFDA.

In order to avoid the risk of registration, Medicilon’s IND application services customizes a practical registration strategy for customers to ensure a timely and accurate submission of the declaration data, This could help our customers to quickly complete the registration review process.


Contact Us 

Email : marketing@medicilon.com

Tel : +86 021 58591500

Website: https://www.medicilon.com

标签：

评论

发表评论

此博客中的热门博文

What is preclinical testing?

In the process of  preclinical testing  of a compound or biological agent into a drug, the compound involved must go through the testing phase. First, we need to identify potential targets that can treat the disease. Then, a variety of compounds or preparations are screened out. Any compound that has shown potential as a drug for the treatment of this disease needs to be tested for toxicity before clinical testing to reduce the possibility of injury. preclinical testing What is the basis of preclinical testing? According to US Food and Drug Administration (FDA) regulations, a series of tests are required before a new drug is approved for use. In the first stage, basic research determines a hypothetical target for the treatment of a certain disease, and then screens small molecules or biological compounds to discover any substance with the potential to treat the disease. Then, a  preclinical research  phase followed, before which, as described above, the potential toxicity of the compou
发表评论
阅读全文

Inventory of the three major in vitro pharmacokinetic research methods

  The metabolic properties of a compound are an essential factor in whether or not it can be used as a drug in the clinical setting, so pharmacokinetic studies of newly synthesized compounds are required in drug development. In vitro incubation with liver microsomes, recombinant CYP450 enzyme lines, and in vitro incubation with hepatocytes are some of the more common in vitro drug metabolism methods. 1. In vitro incubation method with liver microsomes The metabolic stability and metabolic phenotypes of candidate compounds in different species of liver microsomes are good predictors of the metabolic properties of compounds in vivo. They are practical tools for evaluating candidate compounds in the pre-development phase of drug development. Liver microsomes include rat liver microsomes, human liver microsomes, canine liver microsomes, monkey liver microsomes, and mouse liver microsomes. In in vitro incubation of the liver, microsomes are the "gold standard" for in vitro d
发表评论
阅读全文

Novel Parkinson’s Therapies Possible with New Mouse Model

Parkinson's disease (PD) is a neurodegenerative disorder that is marked by the accumulation of the protein, α-synuclein (αS), into clumps known as Lewy bodies, which diminish neural health. Now, researchers from Brigham and Women's Hospital (BWH) report the development of a mouse model to induce PD-like αS aggregation, leading to resting tremor and abnormal movement control. The mouse responds to L-DOPA, similarly to patients with PD. The team's study (“Abrogating Native α-Synuclein Tetramers in Mice Causes a L-DOPA-Responsive Motor Syndrome Closely Resembling Parkinson’s Disease”) on the use of this transgenic mouse model appears in  Neuron . “α-Synuclein (αS) regulates vesicle exocytosis but forms insoluble deposits in PD. Developing disease-modifying therapies requires animal models that reproduce cardinal features of PD. We recently described a previously unrecognized physiological form of αS, α-helical tetramers, and showed that familial PD-causing missense mutati
发表评论
阅读全文